Search tips
Search criteria 


Logo of orphjrdisBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleOrphanet Journal of Rare DiseasesJournal Front Page
Orphanet J Rare Dis. 2010; 5(Suppl 1): P19.
Published online 2010 October 19. doi:  10.1186/1750-1172-5-S1-P19
PMCID: PMC2958408

EU Clinical trial regulation in the environment of rare diseases: time for a change

The clinical trial directive 2001/20/EC is out for public consultation. This session will draw the attention of the challenges faced by Small and Medium Enterprises (SME) companies when developing new products for the rare diseases that affect a very limited number of patients and discuss possible options to overcome the challenges.

Indeed, with only a few patients in each country, clinical trials need to be conducted in many countries in order to enrol the number of patients required to demonstrate benefit/risk. The management of these clinical trials is associated with several issues that slow down the overall process of drug development: administrative hurdles associated with non harmonised regulatory authorisation process as well as cost pressure linked to the need to outsource local activities to several consultants to prepare and manage submission to health authorities and ethic committees.

Today, Europe must streamline its system and all stakeholders should raise their voice to propose specific approaches in order to facilitate the development of new drugs for orphan drugs in a timely manner.

Articles from Orphanet Journal of Rare Diseases are provided here courtesy of BioMed Central